Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus chemotherapy in ovarian cancer
ChiCTR-RPN-17010462Phase 4Recruiting
- Sponsor
- Army Specialized Medical Center
- Start
- Jan 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Army Specialized Medical Center. Primary endpoint: Progression-free survival (PFS). Started Jan 2017; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR-RPN-17010462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-RPN-17010462.